This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

moventig-product-image

MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).1

Click here for Prescribing Information.

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Laxatives are a first-line treatment in constipation, including OIC. However, many patients suffering from OIC do not respond adequately to laxative therapy and require alternative treatment to manage their condition.2

Opioid antagonist drugs designed to act on the bowel and not to cross the blood-brain barrier, such as MOVENTIG, can be helpful in relieving the symptoms of OIC.3

Pharmacotherapy

MOVENTIG

  • INTRODUCTION

    MOVENTIG belongs to a class of drugs known as peripherally acting mu-opioid receptor antagonists (PAMORAs).1 PAMORAs are designed to relieve constipation without compromising the analgesic action of opioids.

  • EFFICACY

    Evidence from clinical studies demonstrating MOVENTIG efficacy in relieving OIC in non-cancer patients.

  • QUALITY OF LIFE IN PATIENTS WITH CANCER

    Evidence from clinical studies demonstrating MOVENTIG's efficacy in relieving OIC in cancer patients.

  • HOW TO PRESCRIBE

    Guidance on how to prescribe MOVENTIG.

  • TOLERABILITY

    MOVENTIG has been shown to be generally well-tolerated for up to 52 weeks.4 Read about the most commonly reported adverse drug reactions.

  • PRESCRIBING INFORMATION

    Direction on prescribing MOVENTIG covering information from dosage ranges to precautions.

Resources

EDUCATION

Guidelines: Pathophysiology and management of opioid-induced constipation

Published in the United European Gastroenterology Journal in 2019, view the European expert consensus statement on the pathophysiology and management of opioid-induced constipation.

LINK TO PUBLICATION

SUPPORT MATERIALS

Guidelines: NICE and SMC

Recommendations for healthcare professionals on the treatment of opioid-induced constipation (OIC) with naloxegol. Developed by NICE (National Institute for Health and Care Excellence) and the SMC (Scottish Medicines Consortium).

LEARN MORE

SUPPORT MATERIALS

OIC training presentation

A helpful overview of the assessment and treatment of opioid-induced constipation (OIC), including naloxegol, to use as an internal resource to help train your colleagues.

DOWNLOAD NOW

MEDICAL EDUCATION

Key Publications and Resources

Keep up-to-date with the latest information, including treatment guidelines for OIC, key publication summaries and downloadable materials.

LEARN MORE

MEDICAL EDUCATION

MASCC Webinar Expert Videos

Hear from expert speakers from the 2020 MASCC (Multinational Associate of Supportive Care in Cancer) virtual meeting. Featuring presentations from Dr. Antoine Lemaire, Dr. Andrew Davies, Dr. Carmen Beato and Dr. Francesca Caputo.

WATCH NOW

MEDICAL EDUCATION

Opioid-induced constipation: a multidisciplinary problem

Professor Andrew Davies, President of MASCC (Multinational Association of Supportive Care in Cancer) explains the difference between opioid-induced constipation (OIC) and other types of constipation, presenting quantitative data from the StOIC 1 study, a large study involving cancer patients in the UK, to highlight the impact of OIC on patients' quality of life.

WATCH NOW

MEDICAL EDUCATION

Professor Drewes on the challenges in OIC

Professor Asbjørn Mohr Drewes talks about the effects of opioids on the gut and the limitations of laxatives in the treatment of OIC.

The effects of opioids on the gut and the limitations of laxatives in the treatment of OIC.

WATCH NOW

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

Average:

  • References

    1. MOVENTIG Summary of Product Characteristics.

    2. Pappagallo M. Am J Surg. 2001; 182(5A Suppl):11S-18S.

    3. Drewes AM et al. Scand J Pain. 2016;11:111-122.

    4. Webster L et al. Alimentary Pharmacology & Therapeutics 2014; 40(7):771-779.

    KKI/INT/MOV/0114 November 2023